Table 2.
WNT/β -catenin pathway inhibitors in melanoma (preclinical study).
Compound | Target Mode of Action |
Research Model | References |
---|---|---|---|
C59 | porcupine inhibitor (synergizes with CTLA4-targeting antibodies in mouse melanoma models) | WM266 human melanoma cell line; B16/F10 mouse melanoma cell line; patient derived Hu-175, Hu-422, Hu-424, Hu-451 human melanoma cell lines | [176] |
WNT-2Ab | WNT2 antibody | LOX, FEMX melanoma cell lines; | [177] |
FJ9 | DVL inhibitor | LOX melanoma cell line | [178] |
G007-LK | tankyrase inhibitor (sensitizes melanoma to PD-1 immune checkpoint blockade) |
B16/F10 mouse melanoma cell line | [179] |
fisetin | (i) GSK3-β inhibitor |
B16F10 mouse melanoma cell line | [180] |
(ii) activator of GSK3-β, DKK1 and WIF-1; FZD and LRP5/6 inhibitor | 451Lu human melanoma cells; athymic (nu/nu) female nude mice | [181] | |
lupeol | blocking the translocation of β-catenin to the nucleus | Mel 928, Mel 1241 and Mel 1011 human melanoma cell lines | [182] |
pentoxifylline | β-catenin | DMBC11, 12, 17, 19, 21 patient-derived melanoma cell lines |
[183] |
PKF115-584 | β-catenin | SKMEL28, A375, BLM, SKMEL19 and 451Lu human melanoma cell lines | [100] |